Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Sakae, Tanosaki"'
Autor:
Naoto Takahashi, Kaichi Nishiwaki, Chiaki Nakaseko, Nobuyuki Aotsuka, Koji Sano, Chikako Ohwada, Jun Kuroki, Hideo Kimura, Michihide Tokuhira, Kinuko Mitani, Kazuhisa Fujikawa, Osamu Iwase, Kohshi Ohishi, Fumihiko Kimura, Tetsuya Fukuda, Sakae Tanosaki, Saori Takahashi, Yoshihiro Kameoka, Hiroyoshi Nishikawa, Hisashi Wakita
Publikováno v:
Haematologica, Vol 103, Iss 11 (2018)
The purpose of this trial was to evaluate the efficacy of 2-year consolidation therapy with nilotinib, at a dose of 300 mg twice daily, for achieving treatment-free remission in chronic myeloid leukemia patients with a deep molecular response (BCR-AB
Externí odkaz:
https://doaj.org/article/d270522d9d4c488f9dc35f3bb6c9b3ce
Autor:
Hideto Tamura, Koiti Inokuchi, Hiroki Sugimori, Takeshi Odajima, Junji Tanaka, Norio Komatsu, Keiichi Moriya, Asaka Onodera, Yasuko Kuribayashi-Hamada, Yuta Kaito, Mika Sunakawa, Toshio Asayama, Shigeki Ito, Sakae Tanosaki, Yutaka Tsukune, Norina Tanaka, Yoichi Imai, Hiroshi Handa, Makoto Sasaki, Asako Tsubota, Risa Takahashi, Mariko Ishibashi
Table S1. Primer sequences Table S2. Patient characteristics in cell - surface SLAMF3 and CD138 expression analysis. Table S3. One hundred and sixty-eight gene sets that were significantly upregulated in SLAMF3-KMS34 cells compared with Î"SLAMF3 cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1760c121042202d5de50c257c0692d93
https://doi.org/10.1158/1541-7786.22514517.v1
https://doi.org/10.1158/1541-7786.22514517.v1
Autor:
Satoshi Shimomura, Shiori Horibuchi-Matsusaki, Sakae Tanosaki, Satoshi Umemura, Tetsuo Yamamoto, Nobuyoshi Kobayashi, Makoto Akashi, Takashi Ikeda, Misao Hachiya, Takako Tominaga, Taiji Tamura
Publikováno v:
Toxicology Letters. 350:283-291
Diethylenetriaminepentaacetate (DTPA) is the most widely used chelating agent for Pu and Am. Volunteers were assigned to receive intravenous injections or aerosol inhalations of 1 g of DTPA on days 1-4; volunteers received once daily injections of Ca
Autor:
Yasuko, Kuribayashi-Hamada, Mariko, Ishibashi, Atsushi, Tatsuguchi, Toshio, Asayama, Namiko, Takada-Okuyama, Asaka, Onodera-Kondo, Keiichi, Moriya, Takehito, Igarashi, Hiroyuki, Onose, Sakae, Tanosaki, Norio, Yokose, Hiroki, Yamaguchi, Hideto, Tamura
Publikováno v:
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi. 89(3)
Primary thyroid lymphoma (PTL) is a rare disease frequently arising against a background of autoimmune thyroiditis. It has recently been reported that the inactivation of the NF-κB negative regulator A20 by deletion and/or mutation could be involved
Publikováno v:
Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences
Erythropoiesis-stimulating agent (ESA) has been recognized as an effective way in the treatment of anemia due to chronic kidney disease, but we sometimes see intractable hemodialysis (HD) patients. The causes of ESA-resistant anemia in HD patients in
Autor:
Yuta Kaito, Yoichi Imai, Yasuko Kuribayashi, Mika Sunakawa, Saori Soeda, Mariko Ishibashi, Asaka Onodera, Yutaka Tsukune, Toshio Asayama, Junji Tanaka, Norina Tanaka, Hiroshi Handa, Makoto Sasaki, Koiti Inokuchi, Sakae Tanosaki, Hideto Tamura, Takeshi Odajima, Keiichi Moriya, Shigeki Ito, Norio Komatsu, Hiroki Sugimori, Ryosuke Kinoshita
Publikováno v:
Oncotarget
The signaling lymphocytic activation molecule family (SLAMF7; also known as CS1 or CD319) is highly expressed on plasma cells from multiple myeloma (MM) as well as natural killer (NK) cells and is a well-known therapeutic target of elotuzumab. The ob
Autor:
Michihide Tokuhira, Jun Kuroki, Osamu Iwase, Fumihiko Kimura, Tetsuya Fukuda, Naoto Takahashi, Koji Sano, Kaichi Nishiwaki, Kinuko Mitani, Kohshi Ohishi, Sakae Tanosaki, Hisashi Wakita, Saori Takahashi, Chikako Ohwada, Kazuhisa Fujikawa, Hiroyoshi Nishikawa, Chiaki Nakaseko, Yoshihiro Kameoka, Nobuyuki Aotsuka, Hideo Kimura
Publikováno v:
Haematologica
The purpose of this trial was to evaluate the efficacy of 2-year consolidation therapy with nilotinib, at a dose of 300 mg twice daily, for achieving treatment-free remission in chronic myeloid leukemia patients with a deep molecular response (BCR-AB
Autor:
Makoto Sasaki, Yasuko Kuribayashi-Hamada, Koiti Inokuchi, Mariko Ishibashi, Risa Takahashi, Yuta Kaito, Junji Tanaka, Asako Tsubota, Shigeki Ito, Norio Komatsu, Asaka Onodera, Yoichi Imai, Norina Tanaka, Hiroki Sugimori, Hiroshi Handa, Keiichi Moriya, Yutaka Tsukune, Mika Sunakawa, Hideto Tamura, Takeshi Odajima, Sakae Tanosaki, Toshio Asayama
Publikováno v:
Molecular cancer research : MCR. 18(4)
The signaling lymphocytic activation molecule family 3 (SLAMF3) is a member of the immunoglobulin superfamily expressed on T, B, and natural killer cells and modulates the activation and cytotoxicity of these cells. SLAMF3 is also expressed on plasma
Autor:
Ryosuke Kinoshita, Junji Tanaka, Hiroshi Handa, Mariko Ishibashi, Yoichi Imai, Norio Komatsu, Yasuko Kuribayashi-Hamada, Koiti Inokuchi, Rimpei Morita, Hideto Tamura, Shigeki Ito, Makoto Sasaki, Sakae Tanosaki, Toshio Asayama, Mika Sunakawa, Norina Hiroike
Publikováno v:
Blood. 134:4361-4361
Introduction: We previously reported that CD86 expressed on tumor cells from multiple myeloma (MM) patients is associated with a proliferative advantage of tumor cells and suppresses the antitumor immune response by inducing the immunosuppressive cyt
Autor:
Norifumi Tsukamoto, Atsushi Isoda, Shigeki Ito, Akio Saito, Toshihide Kawamura, Hideto Tamura, Kayoko Murayama, Morio Matsumoto, Yutaka Tsukune, Tomomi Miyanaga, Keiichi Moriya, Tohru Sakura, Sakae Tanosaki, Hirokazu Murakami, Hirotaka Nakahashi, Hiroshi Handa, Makoto Sasaki, Akihiko Yokohama, Akihiro Ohtsu, Naoya Nakamura, Masaru Kojima, Michiaki Koike
Publikováno v:
International journal of hematology. 106(5)
Although population-based cancer registries have reported lower incidence of Waldenstrӧm macroglobulinemia (WM) in East Asia than in Western countries, previous retrospective analyses have found the clinical features of WM to be similar in these two